LUPUS NEPHRITIS

A. Clinical Research

1. Yap DYH, Chan SCW, Wong PYH, Wong S, Zhang D, Yung S, Lo JMW, Lau CS, Chan TM*. Preemptive increase in immunosuppression for asymptomatic serological reactivation in lupus nephritis patients in clinical remission - a prospective multi-center randomized controlled trial. Kidney Int 2026, in press.
2. Wong CY, Ma BM, Zhang D, Cheung W, Chan TM, Yap DYH*. Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis. Lupus Sci Med 2024; 11: e001152 [Best Paper Finalist 2025, Lupus Foundation of America].
3. Teoh STY, Yap DYH, Tang CSO, Chan TM*. Chronic kidney disease G3-5 in lupus nephritis - prevalence, progression and risk factors. Nephrol Dial Transplant 2025; doi: 10.1093/ndt/gfaf201. 
4. Mejia-Vilet JM, Liu Z, Chan TM*. Choosing the right treatment in patients with lupus nephritis. Clin J Am Soc Nephrol 2022; 17(9): 1399-1402.
5. Yap DYH, Li PH, Tang C, So BYF, Kwan LPY, Chan GCW, Lau CS, Chan TM*. Long-term results of triple immunosuppression with tacrolimus added to mycophenolate and corticosteroids in the treatment of lupus nephritis. Kidney Int Rep 2021; 7: 516-525.
6. Yap DYH, Tam CH, Yung S, Wong S, Tang CSO, Mok TMY, Yuen CKY, Ma MKM, Lau CS, Chan TM*. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrol Dial Transplant 2020; 35: 810-818.
7. Chan TM*. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015; 11: 46-61.
8. Yap DYH, Ma MKM, Mok MMY, Kwan LPY, Chan GCW, Chan TM*. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford) 2014; 53: 2232-2237.
9. Yap DYH, Ma MKM, Mok MMY, Tang CSO, Chan TM*. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013; 52: 480-486.
10. Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM*. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 3248-3254.
11. Chan TM*, Tse KC, Tang CS, Mok MMY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
12. Chan TM*, Li FK, Tang CSO, Wong RW, Fang GX, Ji YL, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN, for the Hong Kong Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.

B. Basic / Translational Research

1. Wong CCY, Gao LY, Xu Y, Chau MKM, Zhang D, Yap DYH, Ying SKY, Lee CK, Yung S*, Chan TM*. Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis. Front Immunol 2024; 15: 1443153.
2. Zhu L, Wong YH, Wong SSH, Cheung SCY, Sher JKH, Lam IYL, Yung S, Chan TM, Yap DYH*. Alterations in exhausted and classical memory B cells in lupus nephritis - relationship with disease relapse. Clin Immunol 2024; 265: 110284.
3. Zhang C, Tam TW, Chau MKM, García Córdoba CA, Yung S*, Chan TM*. Effect of combined mycophenolate and rapamycin treatment on kidney fibrosis in murine lupus nephritis. Front Pharmacol 2022; 13: 866077.
4. Yu KY, Yung S*, Chau MK, Tang CS, Yap DY, Tang AH, Ying SK, Lee CK, Chan TM*. Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. Lupus 2021; 30: 1039-1050.
5. Yap DYH*, Yung S, Lee P, Yam IYL, Tam C, Tang C, Chan TM. B cell subsets and cellular signatures and disease relapse in lupus nephritis. Front Immunol 2020; 11: 1732.
6. Yu KYC, Yung S, Chau MKM, Tang CSO, Yap DYH, Tang AHN, Ying SKY, Lee CK, Chan TM*. Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. Rheumatology (Oxford) 2021; 60: 737-750.
7. Zhang C, Chan CCY, Cheung KF, Chau MKM, Yap DYH, Ma MKM, Chan KW, Yung S*, Chan TM*. Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis. Clin Sci (Lond) 2019; 133: 1721-1744 [Featured in journal front cover].
8. Yung S*, Ng CY, Au KY, Cheung KF, Zhang Q, Zhang C, Yap DY, Chau MK, Chan TM*. Binding of anti-dsDNA antibodies to proximal tubular epithelial cells contributes to renal tubulointerstitial inflammation. Clin Sci (Lond) 2017; 131: 49-67.
9. Yap DYH, Yung S, Zhang Q, Tang C, Chan TM*. Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis. Lupus 2016; 25: 46-53.
10. Yung S*, Ng CY, Ho SK, Cheung KF, Chan KW, Zhang Q, Chau MK, Chan TM*. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-beta1 and collagen synthesis. J Autoimmun 2015; 58: 111-122.
11. Yung S, Cheung KF, Zhang Q, Chan TM*. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 2010; 21: 1912-1927.
12. Yung S, Zhang Q, Zhang CZ, Chan KW, Lui SL, Chan TM*. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum 2009; 60: 2071-2082.
13. Lui SL, Yung S, Tsang R, Zhang F, Chan KW, Tam S, Chan TM*. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008; 4: 305-313.
14. Lui SL*, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol Dial Transplant 2008; 23: 2768-2776.
15. Yung S*, Tsang RC, Leung JK, Chan TM*. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int 2006; 69: 272-280.
16. Yung S*, Tsang RC, Sun Y, Leung JK, Chan TM*. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol 2005; 16: 3281-3294.
17. Chan TM*, Leung JK, Ho SK, Yung S. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 1219-1229.

 

DIABETIC KIDNEY DISEASE

A. Clinical Research

1. Liew A*, Bavanandan S, Hao CM, Lim SK, Prasad N, Sahay M, Susantitaphong P, Roberts V, Wijewickrama E, Wong MG, Tang SCW. Executive Summary of the Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease-2025 Update. Nephrology (Carlton) 2025; 30: e70031.
2. Chan KW, Kwong ASK, Tsui PN, Chan GCW, Choi WF, Yiu WH, Cheung SCY, Wong MMY, Zhang ZJ, Tan KCB, Lao L, Lai KN, Tang SCW*. Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial. Phytomedicine 2024; 130: 155457. 
3. Chan KW, Smeijer DJ, Schechter M, Jongs N, Vart P, Kohan D, Gansevoort RT, Liew A, Tang SCW, Wanner C, de Zeeuw, Heerspink H*. Atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the SONAR trial. Kidney Int 2023; 104: 1219-1226.
4. Heerspink HJL*, Cherney D, Gafor AHA, Górriz JL, Pergola PE, Tang SCW, Desch M, Iliev H, Sun Z, Steubl D, Nangaku M. Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials. J Am Soc Nephrol 2024; 35: 1227–1239. 
5. Chan KW, Kwong ASK, Tan KCB, Lui SL, Chan GCW, Ip TP, Yiu WH, Cowling BJ, Taam Wong V, Lao L, Feng Y, Lai KN, Tang SCW*. Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial. Clin J Am Soc Nephrol 2023; 18: 1163-1174.
6. Chan KW, Yu KY, Yiu WH, Xue R, Lok SWY, Li H, Zou Y, Ma J, Lai KN, Tang SCW*. Potential therapeutic targets of Rehmannia formulations on diabetic nephropathy: a comparative network pharmacology analysis. Front Pharmacol 2022; 13: 794139.
7. Chan KW, Lee PW, Leung CP, Law YK, Gao L, Chan GC, Yiu WH, Lam TP, Tang SC*. PRAgmatic Clinical Trial Design of Integrative MediCinE (PRACTICE): A Focus Group Series and Systematic Review on Trials of Diabetes and Kidney Disease. Front Med 2021; 8: 668913.
8. Chan KW, Chow TY, Yu KY, Xu Y, Zhang NL, Wong VT, Li S*, Tang SCW*. SYmptom-Based STratification of DiabEtes Mellitus by Renal Function Decline (SYSTEM): A Retrospective Cohort Study and Modeling Assessment. Front Med 2021; 8: 682090.
9. Chan GC, Tang SC*. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol Dial Transplant 2016; 31: 359-368.
10. Tang SC*, Leung VT, Chan LY, Wong SH, Chu DW, Leung JC, Lai KN, Ma L, Elbein SC, Bowden DW, Hicks PJ, Comeau ME, Langefeld CD, Freedman BI. The acetyl-coenzyme A carboxylase beta gene (ACACB) is associated with nephropathy in Chinese patients with type 2 diabetes. Nephrol Dial Transplant 2010; 25: 3931-3934.
11. Tang SC, Sharma K. Pathogenesis, Clinical Manifestations, and Natural History of Diabetic Kidney Disease (Ch. 30, Section V). In: Comprehensive Clinical Nephrology, 6th ed., Edited by John Feehally, Jurgen Floege, Richard Johnson and Marcello Tonelli, Elsevier, Philadelphia, USA, 2018, pp 357-375 (8th Edition to be published in 2026).

B. Basic / Translational Research

1. Ma J, Yiu WH, Tang SCW*. Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease. Diabet Med 2025; 42: e15427.
2. Li ZH, Sun ZJ, Tang SCW, Zhao MH, Chen M*, Chang DY*. Finerenone Alleviates Over-Activation of Complement C5a-C5aR1 Axis of Macrophages by Regulating G Protein Subunit Alpha i2 to Improve Diabetic Nephropathy. Cells 2025; 14: 337.
3. Ye S, Zhang M, Zheng X, Li S, Fan Y, Wang Y, Peng H, Chen S, Yang J, Tan L, Zhang M, Xie P, Li X, Luo N, Wang Z, Jin L, Wu X, Pan Y, Fan J, Zhou Y, Tang SCW*, Li B*, Chen W*. YAP1 preserves tubular mitochondrial quality control to mitigate diabetic kidney disease. Redox Biol 2024; 78: 103435.
4. Tang SCW*, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol 2020; 16: 206-222.
5. Li B, Leung JCK, Chan LYY, Yiu WH, Tang SCW*. A global perspective on the crosstalk between saturated fatty acids and Toll-like receptor 4 in the etiology of inflammation and insulin resistance. Prog Lipid Res 2020; 77: 101020.
6. Yiu WH, Li RX, Wong DWL, Wu HJ, Chan KW, Chan LYY, Leung JCK, Lai KN, Sacks SH, Zhou W, Tang SCW*. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrol Dial Transplant 2018; 33: 1323-1332.
7. Hills CE*, Price GW, Wall MJ, Kaufmann TJ, Tang SC, Yiu WH, Squires PE. Transforming Growth Factor Beta 1 Drives a Switch in Connexin Mediated Cell-to-Cell Communication in Tubular Cells of the Diabetic Kidney. Cell Physiol Biochem 2018; 45: 2369-2388.
8. Li RX, Yiu WH, Wu HJ, Wong DW, Chan LY, Lin M, Leung JC, Lai KN, Tang SC*. BMP7 reduces inflammation and oxidative stress in diabetic tubulopathy. Clin Sci (Lond) 2015; 128: 269-280.
9. Yiu WH, Wong DW, Wu HJ, Li RX, Yam I, Chan LY, Leung JC, Lan HY, Lai KN, Tang SC*. Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress. Kidney Int 2016; 89: 386-398 [Featured in journal front cover with Editorial Commentary].
10. Lin M, Yiu WH, Li RX, Wu HJ, Wong DL, Chan LY, Leung JC, Lai KN, Tang SC*. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 2013; 83: 887-900.
11. Lin M, Au WS, Chan AW, Yiu WH, Chan LY, Leung JC, Chan KW, Lai KN, Tang SC*. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 86-102.
12. Tang SC, Leung JC, Chan LY, Tsang AW, Lai KN*. Activation of tubular epithelial cells in diabetic nephropathy and the role of the PPAR-ϒ agonist. J Am Soc Nephrol 2006; 17: 1633-1643.
13. Yung S*, Lee CY, Zhang Q, Lau SK, Tsang RC, Chan TM*. Elevated glucose induction of thrombospondin-1 upregulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol Dial Transplant 2006; 21: 1504-1513.

 

IgA NEPHROPATHY

A. Clinical Research

1. Rovin B*, Barratt J, Cook T, Noronha I, Reich H, Suzuki Y, Tang SC, Floege J. Complement inhibitors and B-cell modifying agents for IgA nephropathy. Kidney Int 2026.
2. Tang SCW, Reich H. Immunoglobulin A nephropathy management: What does the future hold? Kidney Int Suppl 2026.
3. Tang SCW, Nadkarni GN*. From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy. J Am Soc Nephrol 2025; 36: 541-543.
4. Tang SCW, Chen W, Aldworth C, Thomas George A, Kattlun J, Rovira Tomas G, Kroes M, Roccatello D, Przybysz R, Smeets S, Golden K, Garratt-Wheeldon J, Chatterton E, de Courcy J, Lafayette R*. Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients: A Global Real-World Survey. Kidney360 2025; 6: 121-132. 
5. Mathur M*, Barratt J, Chacko B, Chan TM, Kooienga L, Oh K, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia j, Pereira BJG, for the ENVISION Trial Investigators Group. A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med 2024; 390: 20-31. 
6. Rovin BH*, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 2023; 402: 2077-2090.
7. Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, Barratt J, Kramann R*. IgA nephropathy. Nat Rev Dis Primers 2023 ;9: 67.
8. Lie DNW, Chan KW, Tang AHN, Chan ATP, Chan GCW, Lai KN, Tang SC*. Long-term outcomes of add-on direct renin inhibition in IgA nephropathy: a propensity score-matched cohort study. J Nephrol 2023; 36: 407-416.
9. Floege J*, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol 2021; 43: 717-728.
10. Lai KN*, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, Glassock RJ. IgA nephropathy. Nat Rev Dis Primers 2016; 2: 16001.
11. Tang SC, Tang AW, Wong SH, Ho YW, and Lai KN*. Long-term study of mycophenolate mofetil in IgA nephropathy. Kidney Int 2010; 77: 543-549.
12. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN*: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812.

B. Basic / Translational Research

1. Lam DK, Ng NYY, Ting Cheung LP, Ruan Y, Ma J, Yiu WH, Lee CPI, Lau GKK, Tang SCW*. Gut Mucolytic Bacteria Is Associated with IgA Nephropathy. J Am Soc Nephrol 2026; 37: 160-163.
2. Yiu WH, Chan KW, Chan LYY, Leung JCK, Lai KN, Tang SCW*. Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy. Front Physiol 2021; 12: 650888.
3. Leung JCK*, Lai KN, Tang SCW. Role of Mesangial-Podocytic-Tubular Cross-Talk in IgA Nephropathy. Semin Nephrol 2018; 38: 485-495.
4. Tang SC*, Lai KN: The ubiquitin-proteasome pathway and IgA nephropathy: a novel link? Kidney Int 2009; 75: 457-459.

 

TUBULO-INTERSTITIAL INFLAMMATION & FIBROSIS

1. Zou Y, Yiu WH, Lok SWY, Ma J, Feng Y, Lai KN, Tang SCW*. Tubular FoxP2 and kidney fibrosis. J Am Soc Nephrol 2025; 36: 544-558. JASN Editors’ Choice Article in 2025.
2. Xue R, Yiu WH, Chan KW, Lok SWY, Zou Y, Ma J, Li H, Chan LYY, Huang XR, Lai KN, Lan HY, Tang SCW*. Long non-coding RNA NEAT1, NOD-Like nreceptor family protein 3 inflammasome, and acute kidney injury. J Am Soc Nephrol 2024; 35: 998-1015 [Featured in journal front cover with accompanying Editorial Commentary].
3. Li H, Leung JCK, Yiu WH, Chan LYY, Li B, Lok SWY, Xue R, Zou Y, Lai KN, Tang SCW*. Tubular β-catenin alleviates mitochondrial dysfunction and cell death in acute kidney injury. Cell Death Dis 2022; 13: 106.
4. Wong DW, Yiu WH, Chan KW, Li Y, Li B, Lok SW, Taketo MM, Igarashi P, Chan LYY, Leung JCK, Lai KN, Tang SCW*. Activated renal tubular Wnt/β-catenin signaling triggers renal inflammation during overload proteinuria. Kidney Int 2018; 93: 1367-1383.
5. Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, Lai KN*. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003; 111: 515-527.

 

PERITONEAL DIALYSIS & HEMODIALYSIS

A. Clinical Research

1. Mok MMY, Yung S, Kwan LPY, Yip TPS, Lui SL, Chan TM*.  Expanded hemodialysis with Theranova compared with conventional high-flux hemodialysis: Prospective randomized 12-month study. Kidney360 2025; 6: 1143-1157.
2. Cheng FWT, Chau M, Li X, Liang J, Wong ICK*, Tang SCW*. Risk of first peritonitis episode in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: a population-based study. Clin Kidney J 2024; 17: sfae118.
3. Mok MMY, Kwan LPY, Chan GCW, Ma MKM, Wang AYM, Yap DYH, Choy CBY, Tang SCW, Chan TM*. Conversion from Aranesp® to NESP® in dialysis patients -Exploration of dosing strategies and the feasibility of extending the dosing interval. Nephrology (Carlton) 2021; 26:733-741.
4. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, Li CS, Au TC, Lo WK Ho YW, Ng F, Tang C, Chan TM*. A Combination of Biocompatible Peritoneal Dialysis Solutions and Residual Renal Function, Peritoneal Transport and Inflammation Markers: A Randomized Clinical Trial. Am J Kidney Dis 2012; 60: 966-975.
5. Tang SC, Lam B, Leung WS, Chu CM, Ho YW, Ip MS, Lai KN*. Sleep apnea as a novel risk predictor for cardiovascular morbidity and death in peritoneal dialysis patients. Kidney Int 2010; 77: 1031-1038.
6. Tang SC, Lam B, Lai AS, Pang CB, Tso WK, Khong PL, Ip MS, Lai KN*. Improvement in sleep apnea during nocturnal peritoneal dialysis is associated with reduced airway congestion and better uremic clearance. Clin J Am Soc Nephrol 2009; 4: 410-418.
7. Tang SC*, Lai KN. Does automated peritoneal dialysis provide better outcomes than continuous ambulatory peritoneal dialysis? Nat Clin Pract Nephrol 2007; 3: 596-597. 
8. Tang SC, Lam B, Ku PP, Leung WS, Chu CM, Ho YW, Ip MS, Lai KN*. Alleviation of sleep apnea in patients with chronic renal failure by nocturnal cycler-assisted peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2607-2616.
9. Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN, Chan TM*. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42: 173 -183.

B. Basic / Translational Research

1. Jiang N, Zhang Q, Chau KMK, Yip MS, Lui SL, Liu S, Chu KM, Ngan HY, Chan TM*, Yung S*. Anti-fibrotic effect of decorin in peritoneal dialysis and PD-associated peritonitis. EBioMedicine 2020; 52: 102661.
2. Chu JYS, Chau MKM, Chan CCY, Tai ACP, Cheung KF, Chan TM*, Yung S*. miR-200c prevents TGF-1-induced epithelial-to-mesenchymal transition and fibrogenesis in mesothelial cells by targeting ZEB2 and Notch1. Mol Ther Nucleic Acids 2019; 17: 78-91.
3. Yung S, Lui SL, Ng CKF, Yim A, Ma MKM, Lo KY, Chow CC, Chu KH, Chak WL, Lam MF, Yung CY, Yip TP, Wong S, Tang CSO, Ng FS, Chan TM*. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation markers. Perit Dial Int 2015; 35: 147-158.
4. Yung S, Chen XR, Tsang RC, Zhang Q, Chan TM*. Reduction of perlecan synthesis and induction of TGF-beta1 in human peritoneal mesothelial cells due to high dialysate glucose concentration: implication in peritoneal dialysis. J Am Soc Nephrol 2004; 15: 1178-1188.
5. Chan TM*, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003; 64: 519-533. 

 

KIDNEY TRANSPLANTATION

1. Yap DYH, Chu P, Lau K, Ho J, Cheung S, Tang L, Ho C, Chan TM, Kwok J*. HLA-typing of donor-origin cells enriched from urine cell culture of kidney transplanted recipients. HLA 2025; 105: e70253.
2. Yap DYH*, Wu CK, Tang C, Chang KC, Lee WC, Lui DTW, Ma MKM, *Hu TH, Chan TM. A long-term bone and renal safety of TAF treatment in renal transplant recipients. Biomed J 2025; 48: 100833.
3. Ma BMY, Hung IFN, Chan GCW, Tam AR, Chan S, Wong B, Fukuda K, Ohno T, Yung KY, Chan TM*. Case of relapsing COVID-19 in a kidney transplant recipient. Nephrology (Carlton) 2020; 25: 933-936.
4. Yap DYH, Tang C, Fung JYY, Seto WK, Ma MKM, Choy BY, Chan TM*. Long-term data on entecavir treatment for treatment-naive or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients. Transpl Infect Dis 2019; 21: e13143.
5. Ma MKM, Yung S, Chan TM*. mTOR inhibition and kidney diseases. Transplantation 2018; 102 (2S Suppl 1) S32 - S40.
6. Yap DY, Chan TM*. Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience. Nephrology (Carlton) 2016; 21: 438-441.
7. Yap DYH, Yung S, Tang CS, Seto WK, Ma MK, Mok MM, Kwan LP, Chan GC, Choy BY, Yuen MF, Chan TM*. Entecavir treatment in kidney transplant recipients infected with hepatitis B. Clin Transplant 2014; 28: 1010-1015.
8. Ma MKM, Zuo ML, Yap DYH, Mok MM, Kwan LPY, Chan GCW, Siu DCW*, Chan TM*. Chronotropic incompetence, echocardiographic abnormalities and exercise intolerance in renal transplant recipients. J Nephrol 2014; 27: 451-456.
9. Yap DYH, Tang CSO, Yung S, Choy BY, Yuen MF, Chan TM*. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330. 
10. Chan TM*, Tse KC, Tang CSO, Lai KN, Ho SKN. A prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplantation 2004; 4: 1103-1109.
11. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Ho YW, Lai KN, Chan TM*. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-878.
12. Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN*. Pre-emptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252.
13. Chan TM*, Wu PC, Lau JYN, Lai CL, Lok ASF, Cheng IKP. Clinico-pathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 1994; 58: 996-1000.
14. Chan TM*, Lok ASF, Cheng IKP, Ng IOL, Chan KW. Chronic hepatitis C after renal transplantation: treatment with alpha-interferon. Transplantation 1993; 56: 1095-1098.
15. Chan TM, Lok ASF*, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing HCVRNA and anti-HCV assays. Hepatology 1993; 17: 5-8.
16. Chan TM, Lok ASF*, Cheng IKP, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993; 104: 862-868.
17. Chan TM*, Lok ASF, Cheng IKP. Hepatitis C infection among dialysis patients: a comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6: 944-947.
18. Chan TM, Lok ASF*, Cheng IKP. Hepatitis C in renal transplant recipients. Transplantation 1991; 52: 810-813.

GENETIC KIDNEY DISEASES 

1. Ong ACM, Carriazo S, Ma BM, Torra R, Pei Y*. Autosomal Dominant Polycystic Kidney Disease. Lancet 2026: S0140-6736(26)00046-2. doi: 10.1016/S0140-6736(26)00046-2.
2. Ma BM, Franceschini N*. Clinical Genetic Testing in Kidney Disease. Adv Kidney Dis Health 2025 [Manuscript accepted]
3. Ma BM, Milo Rasouly H, Sabatello M*. To Do or Not to Do - Genetic Testing for Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents. Kidney Int. 2025 Jul;108(1):17-19. 
4. Lam WKJ, Lau CS, Luk HM, Au LWC, Chan GCP, Chan WYH, Cheng SSW, Cheng THT, Cheung LL, Cheung YF, Chong JSC, Chu ATW, Chung CCY, Chung KL, Fung CW, Fung ELW, Gao Y, Ho S, Hue SPY, Lee CH, Lee TL, Li PH, Lo HM, Man Lo IF, Loong HHF, Ma BM, Ma W, Pang SYY, Seto WK, Siu SWK, So H, Tam YH, Tang W, Wong RMS, Yap DYH, Yau MLY, Chung BHY*, Lo SV*; Hong Kong Genome Project. The Implementation of Genome Sequencing in Rare Genetic Diseases Diagnosis: a Pilot Study from the Hong Kong Genome Project. Lancet Reg Health West Pac 2025; 55: 101473. 
5. Ma BM, Elefant N, Tedesco M, Bogyo K, Vena N, Murthy SK, Bheda SA, Yang S, Tomar N, Zhang JY, Husain SA, Mohan S, Kiryluk K, Rasouly HM, Gharavi AG*. Developing a Genetic Testing Panel for Evaluation of Morbidities in Kidney Transplant Recipients. Kidney Int 2024; 106: 115-125. [Early Career Researcher Award Best Clinical Science Paper 2024, The Kidney International-International Society of Nephrology]        
   
    

VACCINATION IN CHRONIC KIDNEY DISEASE PATIENTS 

1. Ma BM, Tam AR, Chan KW, Hung IFN, Tang SCW, Yap DY*, Chan TM. Immunogenicity and Safety of the Three-dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: a Systematic Review and Meta-analysis. Kidney Dis 2024 Jan 19;10(2):107-117.
2. Ma BM, Yap DY*. Immunogenicity and Safety of COVID-19 Vaccine in Dialysis Patients. ISPD Asia-Pacific Chapter Newsletter 2022; 20(2):9-11.
3. Ma BM, Tam AR, Chan KW, Ma MK, Hung IFN, Yap DY*, Chan TM. Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A systematic Review and Meta-analysis. Front Med 2022; 9:827-859.  
4. Ma BM, Hung IFN, Chan GCW, Tam AR, Chan SSK, Wong BCK, Fukuda K, Ohno T, Yuen KY, Chan TM*. Case of ‘Relapsing’ COVID-19 in a Kidney Transplant Recipient. Nephrology  2020; 25:933-936.
5. Ma BM, Yap DY, Yip TPS, Hung IFN, Tang SCW, Chan TM*. Vaccination in Patients with Chronic Kidney Disease – Review of Current Recommendations and Recent Advances. Nephrology 2020; 26:5-11 [Featured on the front cover of the journal Nephrology].

 

COMPLEMENT AND COMPLEMENT-MEDIATED KIDNEY DISEASE

1. Rizk DV*, Dixon BP, Chan M, Cook HT, Frazer-Abel A, Tang SCW. Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics. Clin J Am Soc Nephrol 2025 Epub ahead of print. PMID: 41404698.
2. Tang S, Lai KN, Chan TM, Lan HY, Ho SK, Sacks SH*. Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. Am J Kidney Dis 2001; 37: 94-103.
3. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH*. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999; 10: 69-76.
4. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH*. Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 1999; 162: 4336-4341.

1. Romagnani P*, Tang SCW, Weins A, Huber TB, Osafo C, Anders HJ. Podocytopathies. Nat Rev Dis Primers 2025; 11: 87.
2. Ma MKM, Yap DYH, Li CL, Mok MM, Chan GC, Kwan LP, Lai KN, Tang SC*. Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease. QJM-Int J Med 2020; 113: 399-403.
3. Tang S*, Lai FM, Lui YH, Tang CS, Kung NN, Ho YW, Chan KW, Leung JC, Lai KN. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750-1758.
4. Tang S*, Chan TM, Cheng IKP, Lai KN. Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients. QJM-Int J Med 1999; 92: 401-406.

 

GUIDELINES/POLICIES

1. Agarwal R*, Nangaku M, Chen L, Wang AYM, Yanagita M, Bavanandan S, Satirapoj B, Prasad N, Lim SK, Sriwijitkamol A, Roasa EA, Teo BW, Huang CN, Huang CY, Pollock C, Choi SH, Shah DS, Hao C, Kim SG, Jadhav U, Wu MS, Tang SCW. Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia. Clin J Am Soc Nephrol 2025 Epub ahead of print. PMID: 4098647.
2. Teerawattananon Y, Chavarina KK*, Phannajit J, Sutawong J, Yongphiphatwong N, Chawla N, Botwright S, Chuanchaiyakul T, Anothaisintawee T, Arogundade F, Ashuntantang G, Thammatacharee J, Sola L, Chuengsaman P, Chunharas S, Wibulpolprasert S, Tang SCW, Kanjanabuch T, Luyckx V, Ophascharoensuk V, Isaranuwatchai W, Jha V, Praditpornsilpa K, Tungsanga K; Nature Medicine Commission on Dialysis Policy in Low- and Middle-Income Countries. The path to safe, equitable and sustainable dialysis provision for people with chronic kidney disease. Nat Med 2026; 32: 44-46.
3. Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group; Rovin BH*, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, Tang SCW, Trimarch H, Floege J*. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int 2025; 108(4S): S1-71.
4. Rovin BH*, Ayoub IM, Chan TM, Liu ZH, Mejia-Vilet JM, Floege J*. KDIGO 2024 Clinical practice guideline for the management of lupus nephritis. Kidney Int 2024; 105: S1-69.
5. Rovin BH*, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J*. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100: 753-779.
6. Tang SC*, Yu X, Chen HC, Kashihara N, Park HC, Liew A, Goh BL, Nazareth MG, Bunnag S, Tan J, Lun V, Lydia A, Sharma SK, Hoque E, Togtokh A, Ghnaimet M, Jha V. Dialysis care and dialysis funding in Asia. Am J Kidney Dis 2020; 75: 772-781.